Issue Information.
- Published in:
- Clinical Pharmacology in Drug Development, 2022, v. 11, n. 7, p. 781, doi. 10.1002/cpdd.829
- Publication type:
- Article
Works matching IS 2160763X AND DT 2022 AND VI 11 AND IP 7
Results: 13
1
2
Intravenous Perampanel as an Interchangeable Alternative to Oral Perampanel: A Randomized, Crossover, Phase I Pharmacokinetic and Safety Study.
- Published in:
- Clinical Pharmacology in Drug Development, 2022, v. 11, n. 7, p. 878, doi. 10.1002/cpdd.1107
- By:
- Publication type:
- Article
3
A Phase 1 Study to Assess Mass Balance and Absolute Bioavailability of Zimlovisertib in Healthy Male Participants Using a <sup>14</sup>C‐Microtracer Approach.
- Published in:
- Clinical Pharmacology in Drug Development, 2022, v. 11, n. 7, p. 815, doi. 10.1002/cpdd.1109
- By:
- Publication type:
- Article
4
Safety, Tolerability, and Pharmacokinetic Evaluation of Single and Multiple Doses of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib in Healthy Japanese and White Adults.
- Published in:
- Clinical Pharmacology in Drug Development, 2022, v. 11, n. 7, p. 832, doi. 10.1002/cpdd.1094
- By:
- Publication type:
- Article
5
A Single‐blind, Randomized, Single‐dose, Two‐sequence, Two‐period, Crossover Study to Assess the Bioequivalence between Two Oral Tablet Formulations of Rivaroxaban 20 mg in Healthy Mexican Volunteers.
- Published in:
- Clinical Pharmacology in Drug Development, 2022, v. 11, n. 7, p. 826, doi. 10.1002/cpdd.1092
- By:
- Publication type:
- Article
6
P‐Glycoprotein and Breast Cancer Resistance Protein Transporter Inhibition by Cyclosporine and Quinidine on the Pharmacokinetics of Oral Rimegepant in Healthy Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2022, v. 11, n. 7, p. 889, doi. 10.1002/cpdd.1088
- By:
- Publication type:
- Article
7
Absolute Bioavailability, Mass Balance, and Metabolic Profiling Assessment of [<sup>14</sup>C]‐Belumosudil in Healthy Men: A Phase 1, Open‐Label, 2‐Part Study.
- Published in:
- Clinical Pharmacology in Drug Development, 2022, v. 11, n. 7, p. 786, doi. 10.1002/cpdd.1085
- By:
- Publication type:
- Article
8
Phase 1 Studies to Evaluate the Food Effect and Relative Bioavailability of Tablet and Capsule Formulations of Belumosudil in Healthy Adult Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2022, v. 11, n. 7, p. 807, doi. 10.1002/cpdd.1083
- By:
- Publication type:
- Article
9
A Phase 1 Pharmacokinetic Drug Interaction Study of Belumosudil Coadministered With CYP3A4 Inhibitors and Inducers and Proton Pump Inhibitors.
- Published in:
- Clinical Pharmacology in Drug Development, 2022, v. 11, n. 7, p. 795, doi. 10.1002/cpdd.1082
- By:
- Publication type:
- Article
10
A Phase 1, Open‐Label Study to Evaluate the Effect of Food and Concomitant Itraconazole Administration on the Pharmacokinetics of AMG 986 in Healthy Subjects.
- Published in:
- Clinical Pharmacology in Drug Development, 2022, v. 11, n. 7, p. 849, doi. 10.1002/cpdd.1074
- By:
- Publication type:
- Article
11
The Bioequivalence Between Valsartan Oral Solution and Suspension Formulations Developed for Pediatric Use.
- Published in:
- Clinical Pharmacology in Drug Development, 2022, v. 11, n. 7, p. 843, doi. 10.1002/cpdd.1069
- By:
- Publication type:
- Article
12
Single‐Dose Pharmacokinetics and Safety of Ubrogepant in Adults With Hepatic Impairment: Results From an Open‐Label, Phase 1 Trial.
- Published in:
- Clinical Pharmacology in Drug Development, 2022, v. 11, n. 7, p. 857, doi. 10.1002/cpdd.1066
- By:
- Publication type:
- Article
13
Population Pharmacokinetic Modeling and Simulation of TV‐46000: A Long‐Acting Injectable Formulation of Risperidone.
- Published in:
- Clinical Pharmacology in Drug Development, 2022, v. 11, n. 7, p. 865, doi. 10.1002/cpdd.1078
- By:
- Publication type:
- Article